Literature DB >> 29387466

Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey.

Martin R Cowie1, Michel Komajda1.   

Abstract

QUALIFY (QUality of Adherence to guideline recommendations for LIFe-saving treatment in heart failure surveY) showed that good physician adherence to guideline recommendations for angiotensin converting enzyme inhibitors/angiotensin receptor blockers, beta blockers, mineralocorticoid receptor antagonists and ivabradine, with prescription of at least 50 % of recommended dosages, was associated with better 6-month outcomes than moderate or poor adherence. Poor adherence was associated with higher all-cause mortality (hazard ratio 2.21; 95 % CI [1.42-3.44]; p=0.001) and combined heart failure hospitalisation or death (hazard ratio 1.26; 95 % CI [1.08-1.71]; p=0.024) compared with good adherence. Heart failure hospitalisation is a good opportunity to review a patient's medication and to optimise guideline adherence.

Entities:  

Keywords:  Heart failure; adherence; dosage; guidelines; hospitalisation; medication; mortality

Year:  2017        PMID： 29387466      PMCID： PMC5739897          DOI： 10.15420/cfr.2017:13:1

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN： 2057-7540


  21 in total

1.  Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure.

Authors:  G Poelzl; J Altenberger; R Pacher; C H Ebner; M Wieser; A Winter; F Fruhwald; C Dornaus; U Ehmsen; S Reiter; R Steinacher; M Huelsmann; V Eder; A Boehmer; L Pilgersdorfer; K Ablasser; D Keroe; H Groebner; J Auer; G Jakl; A Hallas; M Ess; H Ulmer
Journal:  Int J Cardiol       Date:  2014-05-02       Impact factor: 4.164

2.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

3.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Authors:  M Packer; P A Poole-Wilson; P W Armstrong; J G Cleland; J D Horowitz; B M Massie; L Rydén; K Thygesen; B F Uretsky
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

4.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

5.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.

Authors:  Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen
Journal:  Eur Heart J       Date:  2005-04-12       Impact factor: 29.983

6.  Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.

Authors:  Pascal de Groote; Richard Isnard; Pierre Clerson; Guillaume Jondeau; Michel Galinier; Patrick Assyag; Nacima Demil; Alain Ducardonnet; Jean-François Thebaut; Michel Komajda
Journal:  Eur J Heart Fail       Date:  2009-01       Impact factor: 15.534

7.  Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.

Authors:  Murray Epstein; Nancy L Reaven; Susan E Funk; Karen J McGaughey; Nina Oestreicher; John Knispel
Journal:  Am J Manag Care       Date:  2015-09       Impact factor: 2.229

8.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Authors:  Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson
Journal:  Lancet       Date:  2009-11-16       Impact factor: 79.321

9.  Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.

Authors:  Pamela N Peterson; Paul S Chan; John A Spertus; Fengming Tang; Philip G Jones; Justin A Ezekowitz; Larry A Allen; Frederick A Masoudi; Thomas M Maddox
Journal:  Circ Heart Fail       Date:  2013-10-15       Impact factor: 8.790

10.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.

Authors:  Aldo P Maggioni; Stefan D Anker; Ulf Dahlström; Gerasimos Filippatos; Piotr Ponikowski; Faiez Zannad; Offer Amir; Ovidiu Chioncel; Marisa Crespo Leiro; Jaroslaw Drozdz; Andrejs Erglis; Emir Fazlibegovic; Candida Fonseca; Friedrich Fruhwald; Plamen Gatzov; Eva Goncalvesova; Mahmoud Hassanein; Jaromir Hradec; Ausra Kavoliuniene; Mitja Lainscak; Damien Logeart; Bela Merkely; Marco Metra; Hans Persson; Petar Seferovic; Ahmet Temizhan; Dimitris Tousoulis; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2013-08-26       Impact factor: 15.534
View more
  5 in total

1.  Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.

Authors:  Yirga Legesse Niriayo; Kabaye Kumela; Kidu Gidey; Mulugeta Tarekegn Angamo
Journal:  Biomed Res Int       Date:  2019-04-24       Impact factor: 3.411

2.  Conception and bicentric validation of the proSCANNED score, a simplified bedside prognostic score for Heart Failure patients.

Authors:  Claire Duflos; Kamila Solecki; Michel Galinier; Romain Itier; Jerome Roncalli; Anne-Laure Goger; Bara Mandoraah; Eran Kalmanovich; Fabien Huet; Audrey Agullo; Delphine Delseny; Jean-Christophe Macia; Florence Leclercq; Gregoire Mercier; François Roubille
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

3.  Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia.

Authors:  Abebech Tewabe Gelaye; Mohammed Assen Seid; Lemlem Daniel Baffa
Journal:  Vasc Health Risk Manag       Date:  2022-07-07

4.  Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.

Authors:  Amrita Mukhopadhyay; Harmony R Reynolds; Arielle R Nagler; Lawrence M Phillips; Leora I Horwitz; Stuart D Katz; Saul Blecker
Journal:  BMC Cardiovasc Disord       Date:  2022-08-04       Impact factor: 2.174

5.  Treatment optimization of beta-blockers in chronic heart failure therapy.

Authors:  Yirga Legesse Niriayo; Solomon Weldegebreal Asgedom; Gebre Teklemariam Demoz; Kidu Gidey
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.